Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Studie zu Entrectinib (Rxdx-101) bei Kindern und Jugendlichen mit lokal fortgeschrittenen oder metastasierten soliden oder primären ZNS-Tumoren und/oder ohne zufriedenstellende Behandlungsoptionen (STARTRK-NG)

18. September 2026 aktualisiert von: Hoffmann-La Roche

Eine Open-Label-Studie der Phase 1/2 mit Dosiseskalation und Expansion von Entrectinib (Rxdx-101) in der Pädiatrie mit lokal fortgeschrittenen oder metastasierten soliden oder primären ZNS-Tumoren und/oder ohne zufriedenstellende Behandlungsoptionen

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

69

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Beijing, China
        • Beijing Children's Hospital, Capital Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200082
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Deutschland, 69120
        • Universitaetsklinikum Heidelberg
      • Lyon, Frankreich, 69373
        • Centre Leon Berard
      • Marseille, Frankreich, 13385
        • Hôpital de la Timone, Oncologie Pédiatrique
      • Hong Kong, Hongkong, 00000
        • Hong Kong Children's Hospital
    • Lombardy
      • Milan, Lombardy, Italien, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
    • Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • The Hospital for Sick Children
      • Madrid, Spanien, 28009
        • Hospital Infantil Universitario Nino Jesus
    • California
      • La Jolla, California, Vereinigte Staaten, 92093-0706
        • University of California San Diego
      • San Francisco, California, Vereinigte Staaten, 94158
        • UCSF Benioff Children's Hospital
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Egleston Children's Hospital at Emory University Atlanta
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60637
        • University of Chicago
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21205
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • Dana Farber Cancer Institute
    • Missouri
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Washington University,St. Louis Children's Hospital
    • New York
      • New York, New York, Vereinigte Staaten, 10065
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, Vereinigte Staaten, 43205
        • Nationwide Children's Hospital
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97239
        • Oregon Health & Science Uni
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis, Tennessee, Vereinigte Staaten, 38105
        • St. Jude Children'S Research Hospital
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • Texas Children's Cancer and Hematology Center
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84113
        • Primary Children's Hospital
      • London, Vereinigtes Königreich, SW3 6JJ
        • Royal Marsden Hospital (Sutton)
      • Newcastle upon Tyne, Vereinigtes Königreich, NE1 4LP
        • Royal Victoria Infirmary

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

1 Sekunde bis 18 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Disease status:

    • Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1

    • Phase 2 portion:

      • Part B: Participants must have measurable or evaluable disease, as defined by RANO
      • Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
      • Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
      • Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
  2. Tumor type:

    • Phase 1 portion:

      * Part A: Relapsed or refractory extracranial solid tumors

    • Phase 2 portion

      • Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
      • Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
  3. Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse

  4. Archival tumor tissue from diagnosis or, preferably, at relapse

  5. Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks

  6. Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive

  7. Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment

  8. Adequate organ and neurologic function

  9. Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.

  10. For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug

Exclusion Criteria:

  1. Receiving other experimental therapy
  2. Known congenital long QT syndrome
  3. History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
  4. Known active infections
  5. Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
  6. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
  7. Prior treatment with approved or investigational TRK or ROS1 inhibitors
  8. Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
  9. Patients with NB with bone marrow space-only disease
  10. Incomplete recovery from acute effects of any surgery prior to treatment.
  11. Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
  12. Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Extracranial solid tumors harboring NTRK1/2/3,

Arm closed for further enrollment

ROS1, ALK non-gene fusion molecular alterations

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Andere Namen:
  • RXDX-101
Aktiver Komparator: CNS tumors harboring- NTRK1/2/3, ROS1, ALK

Arm closed for further enrollment

molecular alterations, including gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Andere Namen:
  • RXDX-101
Aktiver Komparator: Neuroblastoma

Arm closed for further enrollment

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Andere Namen:
  • RXDX-101
Aktiver Komparator: Non-neuroblastoma, extracranial solid tumors

Arm closed for further enrollment

harboring - NTRK1/2/3, ROS1, ALK gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Andere Namen:
  • RXDX-101
Aktiver Komparator: Any participant unable to swallow capsules

Arm closed for further enrollment

Any participant who otherwise meet all other eligibility criteria

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Andere Namen:
  • RXDX-101
Aktiver Komparator: Expansion: CNS tumors harboring NTRK1/2/3, ROS1

gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Andere Namen:
  • RXDX-101
Aktiver Komparator: Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1

NTRK 1,2,3 and ROS1 fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Andere Namen:
  • RXDX-101

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maximum Tolerated Dose (MTD)
Zeitfenster: Approximately 6 months

Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03)

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Zeitfenster: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Zeitfenster: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
Zeitfenster: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
Zeitfenster: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Cohort B: Objective Response Rate (ORR)
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR

Approximately 6 months
Cohort D: ORR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR

Approximately 6 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
Zeitfenster: Approximately 24 months

AE, ECG and Labs assessed by NCI CTCAE v4.03

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F1 Formulation
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using minitablets/F15
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F1 Formulation
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation given intact
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using minitablets/F15
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F1 Formulation
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation given intact
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation administered via feeding tube
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using minitablets/F15
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F1 Formulation
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using minitablets/F15
Zeitfenster: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Cohort A, D, or E: Clinical Benefit Rate (CBR)
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: CBR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: CBR
Zeitfenster: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Progression-free Survival (PFS)
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: PFS
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: PFS
Zeitfenster: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Overall Survival (OS)
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1

Approximately 6 months
Cohort B or E: OS
Zeitfenster: Approximately 6 months

Assessed by RANO

Approximately 6 months
Cohort A, D, or E: ORR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: ORR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: ORR
Zeitfenster: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Time to response (TTR)
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: TTR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: TTR
Zeitfenster: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Duration of Response (DOR)
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: DOR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: DOR
Zeitfenster: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Zeitfenster: Approximately 6 months

Assessed by RANO per the investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
Zeitfenster: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Zeitfenster: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Clinical Trials, Hoffmann-La Roche

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

3. Mai 2016

Primärer Abschluss (Geschätzt)

30. Juni 2027

Studienabschluss (Geschätzt)

30. Juni 2027

Studienanmeldedaten

Zuerst eingereicht

4. Januar 2016

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

7. Januar 2016

Zuerst gepostet (Geschätzt)

8. Januar 2016

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

23. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

18. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • RXDX-101-03
  • CO40778 (Andere Kennung: Hoffmann-La Roche)
  • 2023-505088-35-00 (Ctis)
  • 2023 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .